3,3′-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells

Anti-Cancer Drugs

Volumn 21, Issue 9, 2010, Pages 814-822

  Jin, Yucui ^a,b   Zou, Xianghong ^a,b   Feng, Xiaoling ^a,b  

^a CAPITAL NORMAL UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

3,3 Diindolylmethane; breast cancer; Cdc25A; cell cycle arrest; microRNA 21

Indexed keywords

3,3' DIINDOLYLMETHANE; BETA ACTIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ESTROGEN; ESTROGEN RECEPTOR; MICRORNA; MUTANT PROTEIN; PROTEIN CDC25A; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; 3,3'-DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; CDC25A PROTEIN, HUMAN; INDOLE DERIVATIVE; MIRN21 MICRORNA, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRASSICA; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL DIVISION; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CDC25 PHOSPHATASES; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956408743     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833e53ea     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Ali SM, Harvey HA, Lipton A. Metastatic breast cancer: overview of treatment. Clin Orthop Relat Res 2003; 415:S132-S137.
3. Gandini S, Merzenich H, Robertson C, Boyle P. Meta-analysis of studies on breast cancer risk and diet: the role of fruit and vegetable consumption and the intake of associated micronutrients. Eur J Cancer 2000; 36:636-646.
4. Hermann S, Linseisen J, Chang-Claude J. Nutrition and breast cancer risk by age 50: a population-based case-control study in Germany. Nutr Cancer 2002; 44:23-34.
5. Fung TT, Hu FB, Holmes MD, Rosner BA, Hunter DJ, Colditz GA, Willett WC. Dietary patterns and the risk of postmenopausal breast cancer. Int J Cancer 2005; 116:116-121.
6. Hayes JD, Kelleher MO, Eggleston IM. The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur J Nutr 2008; (Suppl 2) 73-88.
7. Holst B, Williamson G. A critical review of the bioavailability of glucosinolates and related compounds. Nat Prod Rep 2004; 21:425-447.
8. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005; 4:1201-1215.
9. Hong C, Firestone GL, Bjeldanes LF. Bcl-2 family-mediated apoptotic effects of 3,30-diindolylmethane (DIM) in human breast cancer cells. Biochem Pharmacol 2002; 63:1085-1097.
10. Sarkar FH, Li Y. Indole-3-carbinol and prostate cancer. J Nutr 2004; 134 (12 Suppl):3493S-3498S.
11. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-3695.
12. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9:1149-1163.
13. Galaktionov K, Beach D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 1991; 67:1181-1194.
14. Sadhu K, Reed SI, Richardson H, Russell P. Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. Proc Natl Acad Sci U S A 1990; 87:5139-5143.
15. Mailand N, Podtelejnikov AV, Groth A, Mann M, Bartek J, Lukas J. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J 2002; 21:5911-5920.
16. Melixetian M, Klein DK, Sorensen CS, Helin K. NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint. Nat Cell Biol 2009; 11:1247-1253.
17. Li M, Yin S, Yuan J, Wei L, Ai JS, Hou Y, et al. Cdc25A promotes G2/M transition in oocytes. Cell Cycle 2008; 7:1301-1302.
18. Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 2006; 18:185-191.
19. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007; 7:495-507.
20. Wu Y, Feng X, Jin Y,Wu Z, Hankey W, Paisie C, et al. A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation. Cancer Prev Res (Phila Pa) 2010; 3:818-828.
21. Saxena S, Jonsson ZO, Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003; 278:44312-44319.
22. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003; 113:673-676.
23. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 2008; 7:464-473.
24. Li Y, VandenBoom TG II, Kong D,Wang Z, Ali S, Philip PA, Sarkar FH. Upregulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69:6704-6712.
25. Melkamu T, Zhang X, Tan J, Zeng Y, Kassie F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2010; 31:252-258.
26. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004; 21:201-230.
27. Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, et al. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 2004; 3:1271-1279.
28. Rahman KM, Sarkar FH, Banerjee S,Wang Z, Liao DJ, Hong X, Sarkar NH. Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol Cancer Ther 2006; 5:2747-2756.
29. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ Jr, et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 2009; 69:8157-8165.
30. Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, et al. Inactivation of NF-kappaB by 3,30-Diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 2007; 6:2757-2765.
31. Rahman KW, Li Y,Wang Z, Sarkar SH, Sarkar FH. Gene expression profiling revealed survivin as a target of 3,30-Diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006; 66:4952-4960.
32. Chen I, McDougal A, Wang F, Safe S. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 1998; 19:1631-1639.
33. Chang X, Tou JC, Hong C, Kim HA, Riby JE, Firestone GL, Bjeldanes LF. 3,30-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 2005; 26:771-778.
34. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421:499-506.
35. Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G Jr, Ranashinge M, et al. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest 2000; 106:753-761.
36. Evans KL. Overexpression of CDC25A associated with poor prognosis in breast cancer. Mol Med Today 2000; 6:459.
37. Goloudina A, Yamaguchi H, Chervyakova DB, Appella E, Fornace AJ Jr, Bulavin DV. Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle 2003; 2:473-478.
38. Jallepalli PV, Lengauer C, Vogelstein B, Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 2003; 278:20475-20479.
39. Rossi L, Bonmassar E, Faraoni I. Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res 2007; 56:248-253.
40. Pothof J, Verkaik NS, Van IW, Wiemer EA, Ta VT, Van der Horst GT, et al. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J 2009; 28:2090-2099.